Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Akynzeo or Olanzapine for Patients Who Experience Breakthrough CINV in Patient Receiving Moderately or Highly Emetogenic Chemotherapy After First Cycle of Chemotherapy

NCT06065722 is registered in ClinicalTrials.gov with Simon Williamson Clinic as lead sponsor.

NCT NCT06065722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06065722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Akynzeo or Olanzapine for Patients Who Experience Breakthrough CINV in Patient Receiving Moderately or Highly Emetogenic Chemotherapy After First Cycle of Chemotherapy
Lead sponsor
Simon Williamson Clinic
Phase
Phase 2
Overall status
Unknown status
Start date
September 9, 2023
Completion date
December 31, 2023
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced nausea and vomiting